Eligibility criteria
Condition
Rheumatoid Arthritis
Sex
Females and Males
Age
0 +
Inclusion criteria
Show details
- All patients receiving Tofacitinib (Xeljanz)
Exclusion criteria
Show details
Not Applicable
You are here
Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
NCT01932372
Last updated on October 11, 2019
About this Study
The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice.
1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy
Occurrences of malignant tumors and serious infections will be compared with a control group.
NCT01932372
Pfizer
Active, not recruiting
Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Based on your search, you may also be interested in
Rheumatoid Arthritis
NCT03885037
All Genders
0+
Years
Tokyo,
Rheumatoid Arthritis
NCT03703817
All Genders
19+
Years
Multiple Sites
Systemic Lupus Erythematosus, Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
NCT03387423
All Genders
18+
Years
Multiple Sites
| Descriptive Information | |||||
|---|---|---|---|---|---|
| Brief Title | Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis | ||||
| Official Title | XELJANZ (REGISTERED) TABLETS 5MG SPECIAL INVESTIGATION (ALL-CASES SURVEILLANCE) | ||||
| Brief Summary | The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice. 1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2? Long-term safety (particularly, malignant tumors and serious infections) and efficacy Occurrences of malignant tumors and serious infections will be compared with a control group. | ||||
| Detailed Description | All the patients whom an investigator prescribes the Xeljanz or Standard of Care for rheumatoid arthritis should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random. | ||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Cohort Time Perspective: Prospective | ||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Probability Sample | ||||
| Study Population | Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to over 8 mg Methotrexate for 3 months treatment. | ||||
| Condition | Rheumatoid Arthritis | ||||
| Intervention |
| ||||
| Study Groups/Cohorts |
| ||||
| Publications * | Not Provided | ||||
| * Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
| Recruitment Information | |||||
| Recruitment Status | Active, not recruiting | ||||
| Actual Enrollment | 10477 | ||||
| Original Estimated Enrollment | 6000 | ||||
| Estimated Study Completion Date | December 15, 2020 | ||||
| Estimated Primary Completion Date | December 15, 2020 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: Not Applicable | ||||
| Sex/Gender |
| ||||
| Ages | Child, Adult, Older Adult | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | Japan | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT01932372 | ||||
| Other Study ID Numbers | A3921194 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product | Not Provided | ||||
| IPD Sharing Statement |
| ||||
| Responsible Party | Pfizer | ||||
| Study Sponsor | Pfizer | ||||
| Collaborators | Not Provided | ||||
| Investigators |
| ||||
| PRS Account | Pfizer | ||||
| Verification Date | September 2019 | ||||
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
BY PHONE
Pfizer Clinical Trials Contact Center
1-800-718-1021